SCHEMBL4512908

SCHEMBL4512908

COc1ccc(S(=O)(=O)Nc2ccc(Cl)cc2)c2c1C[C@@H](N)CC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.57
QRFPR Q96P65 1/20 0.57
ADRA1A P35348 3/20 0.54
HSD11B1 P28845 1/20 0.46
HSD17B2 P37059 1/20 0.46
TP53 P04637 2/20 0.46
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
IDH1 O75874 1/20 0.41
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
GLA P06280 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4962886 1.00 HTR6 (0.57) HTR6QRFPRADRA1AHSD11B1HSD17B2
SCHEMBL4516618 0.90 HTR6 (0.56) HTR6QRFPRADRA1AHSD11B1HSD17B2
SCHEMBL4958896 0.90 HTR6 (0.56) HTR6QRFPRADRA1AHSD11B1HSD17B2
SCHEMBL4961886 0.89 ADRA1A (0.57) HTR6QRFPRADRA1AHSD11B1HSD17B2
SCHEMBL4508627 0.89 ADRA1A (0.57) HTR6QRFPRADRA1AHSD11B1HSD17B2
SCHEMBL4963653 0.88 HTR6 (0.52) HTR6QRFPRADRA1AHSD11B1HSD17B2
SCHEMBL4518506 0.88 HTR6 (0.52) HTR6QRFPRADRA1AHSD11B1HSD17B2
SCHEMBL4507652 0.88 THRB (0.57) HTR6QRFPRADRA1AHSD11B1HSD17B2
SCHEMBL4960350 0.88 THRB (0.57) HTR6QRFPRADRA1AHSD11B1HSD17B2
SCHEMBL4966544 0.87 HTR6 (0.74) HTR6QRFPRADRA1ATP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
EP-1888518-A1 NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126938-A1 NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor HTR6, HTR1D, HTR1A HTR6 1/4885QRFPR 79/4885ADRA1A 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.